The popularity of Viagra initially sparked a period of growth for pharma, nevertheless recent developments present a complicated scenario for investors. Off-patent alternatives are eroding revenue, and persistent https://idarvgj962909.tribunablog.com/the-blue-pill-and-big-pharma-a-precarious-investment-55825416